MedTrace Logo

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2020-12-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

Conditions

Interventions

DRUG

CD101

Intravenous antifungal therapy

DRUG

Caspofungin

Intravenous antifungal therapy

DRUG

Fluconazole

oral antifungal therapy

DRUG

intravenous placebo

normal saline

DRUG

oral placebo

microcrystalline cellulose

Sponsors & Collaborators

  • Cidara Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Taylor Sandison, MD MPH · Cidara Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-26
Primary Completion
2019-06-30
Completion
2019-07-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Bulgaria
  • Canada
  • Greece
  • Hungary
  • Italy
  • Romania
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02734862 on ClinicalTrials.gov